Study of Ibrutinib (a Bruton’s Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
by on Friday, July 20th, 2012 | No Comments
Condition: Mantle Cell Lymphoma
Interventions: Drug: Ibrutinib; Drug: Temsirolimus
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Not yet recruiting – verified July 2012